Dr. Desai discusses the efficacy and longevity of treatment with ruxolitinib cream 1.5% in patients with facial vitiligo based on a recent post-hoc analysis of the TRuE-V1/TRuE-V2 clinical trials.

Chantel Hillestad, RN, MSN, DCNP, FNP-C: Restoring Pigmentation in Patients with Vitiligo
Ms. Hillestad describes the benefits she has seen in treating patients with ruxolitinib, specifically the success in providing repigmentation in all age groups.
PLAY